Prof. Dr. med. Urs Fischer

His main research interest involves diagnosis, management, treatment and outcome of patients with acute neurological diseases, especially of patients with acute ischemic and hemorrhagic stroke. He is participating in multiple preventive, diagnostic and acute treatment trials and stroke registries. He is principal investigator of several international multicenter academic trials on the management of patients with ischaemic and haemorrhagic stroke. The SWIFT DIRECT trial (www.swift-direct.ch ) investigates whether adding intravenous thrombolysis to mechanical thrombectomy improves the patient outcome compared to direct mechanical thrombectomy alone. The ELAN trial (www.elan-trial.ch ) assesses when oral anticoagulation with direct oral anticoagulants in stroke patients with atrial fibrillation can be introduced. The SWITCH trial (www.switch-trial.ch ) investigates whether decompressive craniectomy in addition to the best medical treatment is superior to best medical treatment alone for patients with intracerebral haemorrhage.

Research fields

• Intracerebral hemorrhage
• Endovascular stroke treatment
• Anticoagulation and stroke
• Brain-heart axis
• Sinus venous thrombosis
• Stroke prevention

• European Stroke Organisation Trials Alliance
• All University Hospitals in Switzerland
• Selected partners:
  • University Hospital, Helsinki, Finland
  • Queen Elizabeth University Hospital, Glasgow, UK
  • Universitätsklinikum Hamburg-Eppendorf, Germany
  • Universitätsklinikum Freiburg, Germany
  • Centre Hospitaliaier Universitaire de Toulouse, France
  • National Cerebral and Cardiovascular Center, Osaka, Japan
  • University Center Gasthuisberg, Leuven, Belgium
  • University of Calgary & Foothills Medical Centre, Calgary, Canada